# Clinical Trial to Evaluate Safety, Tolerability, and Pharmacokinetics of SOF-SKN in Healthy Participants

> **NCT07072611** · EARLY_PHASE1 · RECRUITING · sponsor: **Noxopharm Limited** · enrollment: 32 (estimated)

## Conditions studied

- Cutaneous Lupus Erythematosus

## Interventions

- **DRUG:** SOF-SKN 0.25%
- **DRUG:** SOF-SKN 0.5%
- **DRUG:** SOF-SKN 1%
- **DRUG:** SOF-SKN 2%
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07072611
- **Lead sponsor:** Noxopharm Limited
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-14
- **Primary completion:** 2026-02
- **Final completion:** 2026-03
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2025-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07072611

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07072611, "Clinical Trial to Evaluate Safety, Tolerability, and Pharmacokinetics of SOF-SKN in Healthy Participants". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07072611. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*